Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
08 août 2023 16h02 HE
|
Relay Therapeutics, Inc.
Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + fulvestrant data: interim clinical...
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
01 août 2023 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
25 mai 2023 17h01 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
24 mai 2023 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in two upcoming fireside chats: TD Cowen 4th Annual...
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
04 mai 2023 16h05 HE
|
Relay Therapeutics, Inc.
Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clinical trial for RLY-5836, a chemically-distinct PI3Kα pan-mutant...
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
27 avr. 2023 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
19 avr. 2023 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two upcoming fireside chats: Stifel 2023 Targeted Oncology Days, on...
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
18 avr. 2023 10h40 HE
|
Relay Therapeutics, Inc.
Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at target...
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
06 mars 2023 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
01 mars 2023 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month, at the Cowen 43rd Annual Health Care...